medulloblastoma/умор

Веза се чува у привремену меморију

Изаберите тип сортирања

14 резултати

Ewing sarcoma/primitive neuroectodermal tumor arising from the adrenal gland in an adolescent.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

We review the case of an adolescent who presented with flank pain, fatigue and a discrete nonfunctioning adrenal lesion which was found to be an adrenal Ewing sarcoma/primitive neuroectodermal tumor (ES/PNET). The patient was treated with a minimally invasive adrenalectomy as a component of

Acute toxicity profile of craniospinal irradiation with intensity-modulated radiation therapy in children with medulloblastoma: A prospective analysis.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

BACKGROUND To report on the acute toxicity in children with medulloblastoma undergoing intensity-modulated radiation therapy (IMRT) with daily intrafractionally modulated junctions. METHODS Newly diagnosed patients, aged 3-21, with standard-risk (SR) or high-risk (HR) medulloblastoma were eligible.

A phase II study of radioimmunotherapy with intraventricular 131 I-3F8 for medulloblastoma.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

BACKGROUND High-risk and recurrent medulloblastoma (MB) is associated with significant mortality. The murine monoclonal antibody 3F8 targets the cell-surface disialoganglioside GD2 on MB. We tested the efficacy, toxicity, and dosimetry of compartmental radioimmunotherapy (cRIT) with intraventricular

Phase 2 trial of pemetrexed in children and adolescents with refractory solid tumors: a Children's Oncology Group study.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

BACKGROUND Pemetrexed is a multi-targeted antifolate that inhibits key enzymes involved in nucleotide biosynthesis. We performed a phase 2 trial of pemetrexed in children with refractory or recurrent solid tumors, including CNS tumors, to estimate the response rate and further define its toxicity

Esthesioneuroblastoma (olfactory neuroblastoma) with hemorrhage: an unusual presentation.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

Esthesioneuroblastoma (olfactory neuroblastoma) is an uncommon neuroectodermal tumor. Its biological activity ranges from indolent growth to local recurrence and rapid widespread metastasis. Treatment options consist of surgical resection followed by radiation therapy for primary lesions and the

Acute toxicity of proton beam radiation for pediatric central nervous system malignancies.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

BACKGROUND Proton beam therapy (PBT) for pediatric CNS malignancies may reduce late toxicity, but acute toxicity is not well defined. We examined acute toxicity for children with CNS malignancies treated with PBT. METHODS We conducted a retrospective review of 48 children with malignant brain tumors

Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

OBJECTIVE Trabectedin is effective in leiomyosarcoma and liposarcoma, especially the myxoid variant, related to the presence of the FUS-CHOP transcript. We evaluated the efficacy of trabectedin in specific subgroups of patients with soft tissue sarcomas (STS). METHODS Seventy-two patients with

A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

OBJECTIVE A phase I trial of AT9283 (a multitargeted inhibitor of Aurora kinases A and B) was conducted in children and adolescents with solid tumors, to identify maximum-tolerated dose (MTD), safety, efficacy, pharmacokinetics, and pharmacodynamic (PD) activity. METHODS AT9283 was administered as a

A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

The PI3K/Akt/mTOR signaling pathway is aberrantly activated in various pediatric tumors. We conducted a phase I study of the Akt inhibitor perifosine in patients with recurrent/refractory pediatric CNS and solid tumors. This was a standard 3+3 open-label dose-escalation study to assess

Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

OBJECTIVE The Children's Oncology Group conducted a phase II trial of 21-day continuous infusion topotecan to determine the response rate in pediatric patients with recurrent or refractory malignant solid tumors. METHODS Patients with Ewing sarcoma family of tumors (ESFT), osteosarcoma (OS), soft

Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

OBJECTIVE To determine the maximum-tolerated dose (MTD) and to assess the safety, pharmacokinetics, and evidence of antitumor activity of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1 (IGF-1R). METHODS Patients with advanced solid malignancies or non-Hodgkin's

A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

OBJECTIVE This phase I trial was undertaken to determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of the novel smoothened inhibitor sonidegib (LDE225), a potent inhibitor of hedgehog

Craniospinal irradiation using helical tomotherapy for central nervous system tumors.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

The aim of this study was to describe early and late toxicity, survival and local control in 45 patients with primary brain tumors treated with helical tomotherapy craniospinal irradiation (HT-CSI). From 2006 to 2014, 45 patients with central nervous system malignancies were treated with HT-CSI. The

Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors.

Само регистровани корисници могу преводити чланке

Пријави се / Пријави се

OBJECTIVE The hedgehog (Hh) signaling pathway, a key regulator of cell growth and differentiation during development is implicated in pathogenesis of certain cancers. Vismodegib (GDC-0449) is a small-molecule inhibitor of smoothened, a key component of Hh signaling. This phase I trial assessed

Придружите се нашој
facebook страници

Herbal & Natural Medicine

Најкомплетнија база лековитог биља подржана науком

Ради на 55 језика
Биљни лекови потпомогнути науком
Препознавање биљака по слици
Интерактивна ГПС мапа - означите биље на локацији (ускоро)
Читајте научне публикације повезане са вашом претрагом
Претражите лековито биље по њиховим ефектима
Организујте своја интересовања и будите у току са истраживањем вести, клиничким испитивањима и патентима

Упишите симптом или болест и прочитајте о биљкама које би могле да помогну, укуцајте неку биљку и погледајте болести и симптоме против којих се користи.
* Све информације се заснивају на објављеним научним истраживањима